Cornell’s Research Serves the Region and Beyond

BlinkBio Inc.

R&D: Pharmaceuticals

  • Products:
  • New drug discovery platform

BlinkBio Inc. has developed a proprietary technology platform with the potential to revolutionize drug discovery. The novel platform allows the self-assembly of high-affinity drugs from smaller building blocks directly on the biomolecular target inside the cell. The company has successfully raised financing and achieved technical proof of concept. The five-year goal is to establish the BlinkBio platform as a new way to target the “undruggable” in many disease states of high unmet need.

Cornell Connection

BlinkBio Inc. works closely with the founding faculty scientist from Weill Cornell Medicine.